AI has sparked big questions around safety and ethics. OpenAI CEO Sam Altman shares his vision for AI's future and why he thinks the rewards outweigh the risks, live onstage with TED's Chris Anderson.

Sam Altman’s longevity startup Retro Bio seeks to raise $5 billion valuation; Trump pollster advises House GOP on healthcare policy strategy; BMS extends timeline for Cobenfy trial data readout.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is part of a new ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Henry Chandonnet Every time Henry publishes a story, you’ll get an alert straight to your inbox ...

OpenAI has gone wild with compute deals this year, committing to spend far more than its balance sheet can currently sustain. So who takes the fall if it can’t pay? It won’t be Altman. Over the last ...

Accompanying Time’s annual person of the year selection Thursday is a magazine cover that resembles the “Lunch Atop a ...

A leaked internal memo has revealed that OpenAI has warned of “economic headwinds", with CEO Sam Altman conceding that the company is facing "rough vibes" after Google’s Gemini 3 Pro launch. According ...

SAN FRANCISCO, Oct 29 (Reuters) - Soon after ChatGPT was released to the public in late 2022, OpenAI CEO Sam Altman told employees they were on the cusp of a new technological revolution. OpenAI could ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Lauren Edmonds Every time Lauren publishes a story, you’ll get an alert straight to your inbox!